CA2294783A1 - Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine - Google Patents

Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine Download PDF

Info

Publication number
CA2294783A1
CA2294783A1 CA002294783A CA2294783A CA2294783A1 CA 2294783 A1 CA2294783 A1 CA 2294783A1 CA 002294783 A CA002294783 A CA 002294783A CA 2294783 A CA2294783 A CA 2294783A CA 2294783 A1 CA2294783 A1 CA 2294783A1
Authority
CA
Canada
Prior art keywords
cyclodextrin
pharmaceutical compositions
oral administration
active substance
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002294783A
Other languages
English (en)
Other versions
CA2294783C (fr
Inventor
Domenico Fanara
Monique Berwaer
Philippe Nolf
Henri Vranckx
Michel Deleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2294783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2294783A1 publication Critical patent/CA2294783A1/fr
Application granted granted Critical
Publication of CA2294783C publication Critical patent/CA2294783C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques administrables par voie orale comprenant une substance active appartenant à la famille des benzhydrylpipérazines substituées et au moins une cyclodextrine.
CA002294783A 1997-07-03 1998-07-02 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine Expired - Fee Related CA2294783C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
BE9700572 1997-07-03
PCT/BE1998/000100 WO1999001133A1 (fr) 1997-07-03 1998-07-02 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine

Publications (2)

Publication Number Publication Date
CA2294783A1 true CA2294783A1 (fr) 1999-01-14
CA2294783C CA2294783C (fr) 2006-11-14

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294783A Expired - Fee Related CA2294783C (fr) 1997-07-03 1998-07-02 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine

Country Status (21)

Country Link
US (1) US6455533B1 (fr)
EP (1) EP0994710B2 (fr)
JP (2) JP2002508773A (fr)
KR (1) KR100551510B1 (fr)
CN (1) CN1150900C (fr)
AT (1) ATE224717T1 (fr)
AU (1) AU727140B2 (fr)
BE (1) BE1011251A3 (fr)
BR (1) BR9810495A (fr)
CA (1) CA2294783C (fr)
DE (1) DE69808297T3 (fr)
DK (1) DK0994710T4 (fr)
ES (1) ES2184293T5 (fr)
HK (1) HK1029060A1 (fr)
ID (1) ID23806A (fr)
IL (1) IL133397A (fr)
NZ (1) NZ501820A (fr)
PL (1) PL192348B1 (fr)
PT (1) PT994710E (fr)
RU (1) RU2192863C2 (fr)
WO (1) WO1999001133A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
KR20030094244A (ko) * 2001-02-05 2003-12-11 알.피.쉐러 테크놀러지즈 인코포레이티드 약리학적 활성제의 맛을 감소시키기 위한 방법 및 조성물
RU2004123612A (ru) 2002-01-15 2005-04-20 ЮСиБи ФАРШИМ С.А. (CH) Фармацевтическая композиция для перорального применения
IL164106A0 (en) * 2002-04-04 2005-12-18 Pfizer Prod Inc Palatable chewable tablet
WO2006011051A1 (fr) * 2004-07-22 2006-02-02 Pfizer Products Inc. Formulation de masquage du gout comprenant un medicament a dissolution retardee et/ou de la cyclodextrine a dissolution amelioree
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
WO2007144902A1 (fr) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Formulation sous forme de comprimé à mâcher bicouche
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
DK2178521T3 (da) * 2007-07-11 2014-04-28 Fertin Pharma As Stabilt medicinsk tyggegummi omfattende cyclodextrin-inklusionskompleks
US20100189768A1 (en) * 2007-07-11 2010-07-29 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
JPWO2009054432A1 (ja) * 2007-10-26 2011-03-03 第一三共株式会社 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
EP2067469A1 (fr) 2007-11-06 2009-06-10 Teva Pharmaceutical Industries Ltd. Formulations à mâcher
CA2734691C (fr) * 2008-09-05 2017-05-16 Mcneil-Ppc, Inc. Procede de production de comprimes a base de cetirizine
WO2011110939A2 (fr) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Compositions pharmaceutiques de benzhydrylpipérazines substituées
WO2011150859A1 (fr) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Formulations aqueuses orales de méclizine comprenant un agent aromatisant
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
CN103209684A (zh) 2010-09-13 2013-07-17 贝夫-厄克斯股份有限公司 包含异味掩蔽剂的含水药物递送系统
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
EP3122330B1 (fr) * 2014-03-27 2018-07-25 Ucb Farchim, S.A. Compositions pharmaceutiques comprenant de la lévocétirizine
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
WO2022106923A1 (fr) 2020-11-18 2022-05-27 BioPharma Synergies, S. L. Composition de poudre orodispersible comprenant un composé antihistaminique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (da) 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
FR2647343B1 (fr) 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
AU4932093A (en) † 1992-09-24 1994-04-12 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
WO2006011051A1 (fr) * 2004-07-22 2006-02-02 Pfizer Products Inc. Formulation de masquage du gout comprenant un medicament a dissolution retardee et/ou de la cyclodextrine a dissolution amelioree

Also Published As

Publication number Publication date
US20020032217A1 (en) 2002-03-14
HK1029060A1 (en) 2001-03-23
ES2184293T5 (es) 2006-01-16
JP2007091760A (ja) 2007-04-12
WO1999001133A1 (fr) 1999-01-14
CN1150900C (zh) 2004-05-26
JP2002508773A (ja) 2002-03-19
BR9810495A (pt) 2000-09-12
KR100551510B1 (ko) 2006-02-13
AU8201598A (en) 1999-01-25
DE69808297D1 (de) 2002-10-31
IL133397A (en) 2005-07-25
DK0994710T4 (da) 2005-10-17
EP0994710B2 (fr) 2005-09-21
RU2192863C2 (ru) 2002-11-20
AU727140B2 (en) 2000-12-07
DE69808297T3 (de) 2006-01-19
CN1261799A (zh) 2000-08-02
ID23806A (id) 2000-05-11
PL192348B1 (pl) 2006-10-31
PL337794A1 (en) 2000-09-11
BE1011251A3 (fr) 1999-06-01
EP0994710A1 (fr) 2000-04-26
NZ501820A (en) 2000-10-27
CA2294783C (fr) 2006-11-14
US6455533B1 (en) 2002-09-24
PT994710E (pt) 2003-02-28
EP0994710B1 (fr) 2002-09-25
IL133397A0 (en) 2001-04-30
DK0994710T3 (da) 2003-01-20
KR20010014398A (ko) 2001-02-26
DE69808297T2 (de) 2003-04-17
ATE224717T1 (de) 2002-10-15
ES2184293T3 (es) 2003-04-01

Similar Documents

Publication Publication Date Title
CA2294783A1 (fr) Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine
BG106030A (en) Pharmaceutical composition
MY118151A (en) Pharmaceutical formulations containing voriconazole.
AU2274201A (en) Compounds and compositions for delivering active agents
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
AU2845599A (en) Pharmaceutical compositions and their use
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
AP9901534A0 (en) Pharmaceutical formulations.
AU5402296A (en) Pharmaceutical composition for transdermic administration
AU6818196A (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
AU5651696A (en) Substituted 1-phenyl-3-pyrazolecarboxamides active on nurotensin receptors, their preparation and pharmaceutical compositions containing them
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
PL346764A1 (en) New oral formulation for 5-ht4
AU5812800A (en) Pharmaceutical preparation
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
EP1273301A3 (fr) Préparations pharmaceutiques comprenant des principes actifs susceptibles d'administration illicite
AU5072000A (en) Pharmaceutical composition for nasally administering water-soluble active substances
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2502301A (en) Medicament and combination of compatible medicaments
AU3860797A (en) Pharmaceutical formulations for oral administration
AU2169799A (en) Pharmaceutical composition for nasal administration of thiocolchicoside
AU1584800A (en) Immuno-active, anti-cancer and pharmacologically active polysaccharide compoundsand pharmaceutical compositions containing the polysaccharide compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150702